All of the following antiretroviral drugs produce dyslipidemia except:
**Question:** All of the following antiretroviral drugs produce dyslipidemia except:
A. Indinavir
B. Raltegravir
C. Tenofovir
D. Efavirenz
**Core Concept:**
Dyslipidemia is a condition characterized by abnormal lipid levels in the blood, leading to an increased risk of cardiovascular diseases. Antiretroviral drugs are medications used to treat human immunodeficiency virus (HIV) infection. Several antiretroviral drugs can cause dyslipidemia due to their effects on lipid synthesis and/or clearance pathways in the liver.
**Why the Correct Answer is Right:**
Raltegravir is a selective integrase inhibitor, which inhibits HIV integration into the host genome. Unlike other antiretroviral drugs, raltegravir does not directly affect lipid synthesis or clearance pathways in the liver, making it the correct answer.
**Why Each Wrong Option is Incorrect:**
A. Indinavir is a protease inhibitor, which interferes with HIV protease enzyme responsible for processing viral proteins. Indinavir is known to cause dyslipidemia due to its effects on liver lipoprotein synthesis and lipoprotein lipase activity.
B. Tenofovir is a nucleoside reverse transcriptase inhibitor, which inhibits HIV reverse transcriptase enzyme. Tenofovir can cause dyslipidemia due to its effects on liver lipid synthesis and lipoprotein clearance.
C. Efavirenz is an non-nucleoside reverse transcriptase inhibitor, which competitively inhibits the HIV reverse transcriptase enzyme. Efavirenz is known to cause dyslipidemia due to its effects on liver lipid synthesis and lipoprotein clearance.
**Clinical Pearl:**
Understanding the pharmacological mechanisms of antiretroviral drugs can help predict and manage their side effects. While treating HIV patients, healthcare professionals should be aware of the potential dyslipidemia associated with nucleoside and non-nucleoside reverse transcriptase inhibitors (e.g., indinavir, tenofovir, efavirenz) and monitor lipid profiles in patients on these medications to prevent and manage dyslipidemia-related cardiovascular complications.